An observational study in Hypercholesterolaemia, sponsored by Federico II University. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-29.
Sponsored by Federico II University · Observational
Evaluation of adherence, persistence and efficacy of treatment with alirocumab 300 mg in a real-life Italian population.
The study population includes patients from Italy, who have received alirocumab 300mg as part of routine clinical management of their hyperlipidaemia at time of enrollment, based on national reimbursement criteria.
- Patients under alirocumab 300mg treatment.
Exclusion Criteria:
Subjects with hyperlipidaemia
Drug: Praluent (Alirocumab)
Alirocumab 300 mg injection
Description of adherence of treatment with alirocumab 300mg in a real-life Italian population.
Adherence will be assessed in terms of Medical Possession Ratio (MPR) which is defined as the ratio between the treatment units dispensed during the treatment period and the duration of the treatment period itself.
Time frame: 6-12-24-36 months
Description of persistence of treatment with alirocumab 300mg in a real-life Italian population.
Persistence will be assessed in terms of therapeutic continuity from the start of treatment to enrollment.
Time frame: 6-12-24-36 months
Description of efficacy of treatment with alirocumab 300mg in a real-life Italian population.
Efficacy of treatment will be evaluated as a change in the LDL (deltaLDL) value from the start of treatment (percentage and absolute value).
Time frame: 6-12-24-36 months
Description of safety of treatment with alirocumab 300mg in a real-life Italian population.
Safety will be evaluated in terms of adverse reactions or intolerance to the drug.
Time frame: 6-12-24-36 months
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Federico II University